QuantRx(R) Biomedical to Present at Invest Northwest(R) 2007, March 20-21 in Seattle as Part of Broader Investment Community Outreach
DOYLESTOWN, PA -- (MARKET WIRE) -- January 16, 2007 -- QuantRx® Biomedical Corporation (OTCBB: QTXB), an emerging leader in the research and development of medical diagnostic platforms and products, today announced that its management will present at Invest Northwest®, the Pacific Northwest's premier life science investor conference, scheduled Tuesday and Wednesday, March 20-21, 2007, at Seattle's Bell Harbor International Conference Center.
QuantRx is among 50 foremost biotechnology and biomedical companies of the Western United States and Canada to be selected to participate in the conference, which attracts leading members of the financial and investment communities. The Company's state-of-the-art research and development facility is located in Portland, Oregon.
Presenting at the conference will be Walter Witoshkin, Chairman and Chief Executive Officer of QuantRx. QuantRx was invited to participate in the conference based on its emerging presence in creating and delivering innovative medical diagnostic platforms and products for the professional, institutional and consumer markets.
"QuantRx continues to receive consistent support from the investment community. We look forward to updating Invest Northwest participants on our substantial growth prospects -- the 2007 introductions of a number of QuantRx medical diagnostic products and the ongoing development of our solid portfolio of innovative technology platforms," Mr. Witoshkin said.
"In balance with our operating growth initiatives, an important component of our business strategy in 2007 is to extend our relationships with investment professionals through recurrent participation in trade and financial conferences, such as Invest Northwest, in the nation's major money centers. These activities underscore our resolve to broaden the awareness of the Company within the investment and business communities toward building value for shareholders and our business partners," Mr. Witoshkin added.
About QuantRx Biomedical
QuantRx Biomedical Corporation (OTCBB: QTXB) is an emerging leader in the research and development of medical diagnostics, specializing in creating, acquiring and commercializing diagnostic platforms and developing products, based on its core intellectual property, for both professional and consumer use. The Company's technology portfolio includes rapid point-of-care testing products that bring medical information directly to the healthcare provider or the patient; genome-based diagnostics chips for medical professionals and institutions; PAD technology for diagnosis and treatment of women's health concerns and other medical needs; and diagnostic imaging products for the positron emission tomography (PET) market.
QuantRx has corporate offices in Doylestown, Pennsylvania, and its research and development center in Portland, Oregon. Additionally, the Company holds significant positions in FluoroPharma, Inc., a Boston-based molecular imaging company, and Genomics USA, a Chicago-based developer of microarray technology for DNA testing.
For information about the conference, which is organized by the Seattle-based Washington Biotechnology & Biomedical Association with support of the region's other biosciences organizations, see .
This release may contain forward-looking statements within the meaning of the federal securities laws. Such forward-looking statements reflect, among other things, management's current expectations, plans and strategies, and anticipated financial results, all of which are subject to known and unknown risks, uncertainties and factors that may cause our actual results to differ materially from those expressed or implied by these forward-looking statements. Many of these risks are beyond our ability to control or predict including the Company's need for additional funds, the Company's dependence on a limited number of imaging compounds, the early state of the products the Company is developing, uncertainties relating to clinical trials and regulatory reviews, competition and dependence on collaborative partners, the Company's ability to avoid infringement of the patent rights of others, and the Company's ability to obtain adequate patent protection and to enforce these rights. Because of these risks, uncertainties and assumptions, you should not place undue reliance on these forward-looking statements. Furthermore, forward-looking statements speak only as of the date they are made. QuantRx does not undertake any obligation to update or review any such forward-looking information, whether as a result of new information, future events or otherwise.